The efficacy, safety and positioning of inhaled corticosteroids (ICS) in the treatment of
patients with chronic obstructive pulmonary disease (COPD) is much debated, since it can …

Chronic obstructive pulmonary disease (COPD) is a common, complex, and heterogeneous
disorder that is responsible for substantial and growing morbidity, mortality, and health-care …

Rationale: There are no studies on withdrawal of inhaled corticosteroids in patients on long-
term triple therapy in the absence of frequent exacerbations. Objectives: To evaluate the …

Inhaled corticosteroids (ICS) combined with bronchodilators can reduce the frequency of
exacerbations in some patients with chronic obstructive pulmonary disease (COPD). There …

La enfermedad pulmonar obstructiva crónica (EPOC) presenta una gran heterogeneidad
clínica, por lo que su tratamiento se debe individualizar según el nivel de riesgo y el …

Background Long‐acting bronchodilators such as long‐acting β‐agonist (LABA), long‐
acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations …

Background Real-world prescription pathways leading to triple therapy (TT)(inhaled
corticosteroid [ICS] plus long-acting β2-agonist bronchodilator [LABA] plus long-acting …

Inhaled therapies are the backbone of asthma and chronic obstructive pulmonary disease
management, helping to target therapy at the airways. Adherence to prescribed treatment is …

Background It has been suggested that withdrawal of inhaled corticosteroids (ICS) in COPD
patients on maintenance treatment results in deterioration of symptoms, lung function and …

Background: Whether all types of inhaled corticosteroids (ICSs) would increase the
pneumonia risk in patients with chronic obstructive pulmonary disease (COPD) remains …